308 related articles for article (PubMed ID: 36742317)
1. Metabolism of NK cells during viral infections.
Osuna-Espinoza KY; Rosas-Taraco AG
Front Immunol; 2023; 14():1064101. PubMed ID: 36742317
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
Di Vito C; Calcaterra F; Coianiz N; Terzoli S; Voza A; Mikulak J; Della Bella S; Mavilio D
Front Immunol; 2022; 13():888248. PubMed ID: 35844604
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell effector functions in antiviral defense.
Piersma SJ; Brizić I
FEBS J; 2022 Jul; 289(14):3982-3999. PubMed ID: 34125493
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells in antiviral immunity.
Björkström NK; Strunz B; Ljunggren HG
Nat Rev Immunol; 2022 Feb; 22(2):112-123. PubMed ID: 34117484
[TBL] [Abstract][Full Text] [Related]
5. Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications.
Letafati A; Ardekani OS; Naderisemiromi M; Norouzi M; Shafiei M; Nik S; Mozhgani SH
Virol J; 2024 Jan; 21(1):18. PubMed ID: 38216935
[TBL] [Abstract][Full Text] [Related]
6. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells.
Witkowski M; Tizian C; Ferreira-Gomes M; Niemeyer D; Jones TC; Heinrich F; Frischbutter S; Angermair S; Hohnstein T; Mattiola I; Nawrath P; McEwen S; Zocche S; Viviano E; Heinz GA; Maurer M; Kölsch U; Chua RL; Aschman T; Meisel C; Radke J; Sawitzki B; Roehmel J; Allers K; Moos V; Schneider T; Hanitsch L; Mall MA; Conrad C; Radbruch H; Duerr CU; Trapani JA; Marcenaro E; Kallinich T; Corman VM; Kurth F; Sander LE; Drosten C; Treskatsch S; Durek P; Kruglov A; Radbruch A; Mashreghi MF; Diefenbach A
Nature; 2021 Dec; 600(7888):295-301. PubMed ID: 34695836
[TBL] [Abstract][Full Text] [Related]
7. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.
Ghasemzadeh M; Ghasemzadeh A; Hosseini E
Hum Immunol; 2022 Jan; 83(1):86-98. PubMed ID: 34583856
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity.
Kim H; Byun JE; Yoon SR; Koohy H; Jung H; Choi I
Cell Immunol; 2022 Jan; 371():104454. PubMed ID: 34773897
[TBL] [Abstract][Full Text] [Related]
9. Glycolysis and Oxidative Phosphorylation Play Critical Roles in Natural Killer Cell Receptor-Mediated Natural Killer Cell Functions.
Wang Z; Guan D; Wang S; Chai LYA; Xu S; Lam KP
Front Immunol; 2020; 11():202. PubMed ID: 32153568
[TBL] [Abstract][Full Text] [Related]
10. Metabolic requirements of NK cells during the acute response against retroviral infection.
Littwitz-Salomon E; Moreira D; Frost JN; Choi C; Liou KT; Ahern DK; O'Shaughnessy S; Wagner B; Biron CA; Drakesmith H; Dittmer U; Finlay DK
Nat Commun; 2021 Sep; 12(1):5376. PubMed ID: 34508086
[TBL] [Abstract][Full Text] [Related]
11. Viral Evasion of Natural Killer Cell Activation.
Ma Y; Li X; Kuang E
Viruses; 2016 Apr; 8(4):95. PubMed ID: 27077876
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell responses to viral infection.
Brandstadter JD; Yang Y
J Innate Immun; 2011; 3(3):274-9. PubMed ID: 21411975
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic depletion of natural killer cells controls persistent infection.
Waggoner SN; Daniels KA; Welsh RM
J Virol; 2014 Feb; 88(4):1953-60. PubMed ID: 24284324
[TBL] [Abstract][Full Text] [Related]
14. Viral Infection of Human Natural Killer Cells.
van Erp EA; van Kampen MR; van Kasteren PB; de Wit J
Viruses; 2019 Mar; 11(3):. PubMed ID: 30870969
[TBL] [Abstract][Full Text] [Related]
15. GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
Rudd CE
Front Immunol; 2020; 11():1638. PubMed ID: 32695123
[TBL] [Abstract][Full Text] [Related]
16. Immunometabolism and natural killer cell responses.
O'Brien KL; Finlay DK
Nat Rev Immunol; 2019 May; 19(5):282-290. PubMed ID: 30808985
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
Bortolotti D; Gentili V; Rizzo S; Rotola A; Rizzo R
Cells; 2020 Aug; 9(9):. PubMed ID: 32859121
[TBL] [Abstract][Full Text] [Related]
18. NK cells in COVID-19-from disease to vaccination.
Hammer Q; Cuapio A; Bister J; Björkström NK; Ljunggren HG
J Leukoc Biol; 2023 Oct; 114(5):507-512. PubMed ID: 36976012
[TBL] [Abstract][Full Text] [Related]
19. Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates.
Malengier-Devlies B; Filtjens J; Ahmadzadeh K; Boeckx B; Vandenhaute J; De Visscher A; Bernaerts E; Mitera T; Jacobs C; Vanderbeke L; Van Mol P; Van Herck Y; Hermans G; Meersseman P; Wilmer A; Gouwy M; Garg AD; Humblet-Baron S; De Smet F; Martinod K; Wauters E; Proost P; Wouters C; Leclercq G; Lambrechts D; Wauters J; Matthys P
Front Immunol; 2022; 13():861251. PubMed ID: 36275702
[TBL] [Abstract][Full Text] [Related]
20. Immunometabolism of T cells and NK cells: metabolic control of effector and regulatory function.
Poznanski SM; Barra NG; Ashkar AA; Schertzer JD
Inflamm Res; 2018 Oct; 67(10):813-828. PubMed ID: 30066126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
